FeesSafety
Pluang+

Avalyn Pharma advances lung-targeted antifibrotics with key trial data due in late 2027 and potential market impact.

Market News
19 Nov 2026, 13:19 WIB
Seeking Alpha
View Source
Bullish
Avalyn Pharma advances lung-targeted antifibrotics with key trial data due in late 2027 and potential market impact.

Avalyn Pharma is developing lung-directed delivery methods for antifibrotic drugs aimed at treating pulmonary fibrosis, potentially improving tolerability by reducing systemic side effects. Their lead candidate AP01 targets progressive pulmonary fibrosis (PPF) with a Phase 2b trial readout expected in the second half of 2027, alongside data from AP02 and AP03 candidates. A decision on Tyvaso in April could support infrastructure for nebulized treatments, benefiting Avalyn's launch. While the company's pipeline is valued under $1 billion, risks remain from trial outcomes and future funding needs, as management expects cash to last until 2029 but anticipates further capital raises for commercial expansion.

Avalyn Pharma's development in pulmonary fibrosis treatment is noted alongside Pluang's Health-sector market snapshot as of Nov 19, 2026 17:01 WIB: out of 150 priced US health stocks, 83 rose and 58 fell. Notable movers include ACADIA Pharmaceuticals Inc. (ACAD) at USD 17.26 with a 3.20% decline and 100% buy order activity, Nuwellis Inc (NUWE) at USD 3.95 with a 3.13% gain and full buy order activity, and Bio-Rad Laboratories (BIO) at USD 358.60 with a 3.13% drop. Typical hold times range from 34 to 77 days among these stocks.

More News

Bath & Body Works beats earnings and revenue estimates, launches $500M buyback, raises sales outlook.

Bath & Body Works beats earnings and revenue estimates, launches $500M buyback, raises sales outlook.

Bath & Body Works reported third-quarter earnings per share of $0.26, surpassing the $0.12 estimate, and revenue of $1.58 billion, above the $1.55 billion estimate. The company also announced a new $500 million share repurchase program and raised its...

Company Fundamentals
Bullish
52 minutes ago
Pasqal integrates quantum processors natively into Slurm for easier HPC management with NVIDIA support.

Pasqal integrates quantum processors natively into Slurm for easier HPC management with NVIDIA support.

Pasqal has integrated its neutral-atom quantum processors natively into Slurm's Hierarchical Resources (HRES) system, recently expanded by NVIDIA. This allows supercomputing centers to manage quantum processing units (QPUs) alongside CPUs and GPUs mo...

Market News
Bullish
56 minutes ago
SpaceX shifts focus from satellite internet profits to rapid AI growth, trading at a high valuation.

SpaceX shifts focus from satellite internet profits to rapid AI growth, trading at a high valuation.

SpaceX currently earns most of its profits from its Starlink satellite internet service, which has 13.6 million subscribers and generated $2.37 billion in operating income last quarter. However, the company is aggressively pivoting towards artificial...

Market News
Bullish
1 hour ago
TSMC and Applied Materials poised for strong growth amid booming semiconductor demand.

TSMC and Applied Materials poised for strong growth amid booming semiconductor demand.

Despite a recent 25% drop in semiconductor stocks, TSMC and Applied Materials stand out due to their dominant market positions and growth potential. TSMC leads with a 73% share in the foundry market, benefiting from AI chip demand and planned price h...

Market News
Bullish
1 hour ago
Stock market faces sharp correction risk amid AI turmoil and rising interest rates, Buffett advises cautious investing.

Stock market faces sharp correction risk amid AI turmoil and rising interest rates, Buffett advises cautious investing.

The stock market is vulnerable to a sharp correction due to rising interest rates and uncertainty in the AI industry following Nvidia CEO Jensen Huang's departure amid scandal. Inflation pressures have led the Federal Reserve to raise rates, potentia...

Bearish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App